J Gastric Cancer.  2011 Mar;11(1):7-15.

Prevalence, Pathophysiology, Screening and Management of Osteoporosis in Gastric Cancer Patients

• Lim JS
• Lee JI

Abstract

Osteoporosis in gastric cancer patients is often overlooked or even neglected despite its high prevalence in these patients. Considering that old age, malnutrition, chronic disease, chemotherapy, decreased body mass index and gastrectomy are independent risk factors for osteoporosis, it is reasonable that the prevalence of osteoporosis in gastric cancer patients would be high. Many surviving patients suffer from back pain and pathological fractures, which are related to osteoporosis. Fractures have obvious associated morbidities, negative impact on quality of life, and impose both direct and indirect costs. In the era of a >55.6% 5-year survival rate of gastric cancer and increased longevity in gastric cancer patients, it is very important to eliminate common sequelae such as osteoporosis. Fortunately, the diagnosis of osteoporosis is well established and many therapeutic agents have been shown to be effective and safe not only in postmenopausal females but also in elderly males. Recently, effective treatments of gastric cancer patients with osteoporosis using bisphosphonates, which are commonly used in postmenopausal woman, were reported.

Keyword

Stomach neoplasms; Osteoporosis; Prevalence; Diagnosis; Therapeutics

MeSH Terms

Aged
Back Pain
Body Mass Index
Chronic Disease
Diphosphonates
Female
Fractures, Spontaneous
Gastrectomy
Humans
Longevity
Male
Malnutrition
Mass Screening
Osteoporosis
Prevalence
Quality of Life
Risk Factors
Stomach Neoplasms
Survival Rate
Diphosphonates

Figure

• 

  Fig. 1 The management approach for osteoporosis in gastric cancer patients. DXA = dual-energy X-ray absorptiometry; PTH = parathyroid hormone.

Reference

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005. 55:74–108.

2. Lee HJ, Yang HK, Ahn YO. Gastric cancer in Korea. Gastric Cancer. 2002. 5:177–182.

3. Liedman B. Symptoms aft er total gastrectomy on food intake, body composition, bone metabolism, and quality of life in gastric cancer patients--is reconstruction with a reservoir worthwhile? Nutrition. 1999. 15:677–682.

4. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003. 124:795–841.

5. Lim JS, Kim SB, Bang HY, Cheon GJ, Lee JI. High prevalence of osteoporosis in patients with gastric adenocarcinoma following gastrectomy. World J Gastroenterol. 2007. 13:6492–6497.

6. Iba K, Wada T, Takada J, Yamashita T. Multiple insufficiency fractures with severe osteoporosis. J Orthop Sci. 2003. 8:717–720.

7. Cui LH, Choi JS, Shin MH, Kweon SS, Park KS, Lee YH, et al. Prevalence of osteoporosis and reference data for lumbar spine and hip bone mineral density in a Korean population. J Bone Miner Metab. 2008. 26:609–617.

8. Liedman B, Bosaeus I, Mellström D, Lundell L. Osteoporosis aft er total gastrectomy. Results of a prospective, clinical study. Scand J Gastroenterol. 1997. 32:1090–1095.

9. Adachi Y, Shiota E, Matsumata T, Iso Y, Yoh R, Kitano S. Osteoporosis after gastrectomy: bone mineral density of lumbar spine assessed by dual-energy X-ray absorptiometry. Calcif Tissue Int. 2000. 66:119–122.

10. Orwoll ES, Bevan L, Phipps KR. Determinants of bone mineral density in older men. Osteoporos Int. 2000. 11:815–821.

11. Baek KH, Jeon HM, Lee SS, Lim DJ, Oh KW, Lee WY, et al. Short-term changes in bone and mineral metabolism following gastrectomy in gastric cancer patients. Bone. 2008. 42:61–67.

12. Melton LJ 3rd, Crowson CS, Khosla S, O'Fallon WM. Fracture risk aft er surgery for peptic ulcer disease: a population-based cohort study. Bone. 1999. 25:61–67.

13. Mellström D, Rundgren A. Long-term effects after partial gastrectomy in elderly men. A longitudinal population study of men between 70 and 75 years of age. Scand J Gastroenterol. 1982. 17:433–439.

14. Klein KB, Orwoll ES, Lieberman DA, Meier DE, McClung MR, Parfitt AM. Metabolic bone disease in asymptomatic men after partial gastrectomy with Billroth II anastomosis. Gastroenterology. 1987. 92:608–616.

15. Bisballe S, Eriksen EF, Melsen F, Mosekilde L, Sørensen OH, Hessov I. Osteopenia and osteomalacia after gastrectomy: interrelations between biochemical markers of bone remodelling, vitamin D metabolites, and bone histomorphometry. Gut. 1991. 32:1303–1307.

16. Eddy RL. Metabolic bone disease after gastrectomy. Am J Med. 1971. 50:442–449.

17. Kwon SJ, Hahm JS, Cho YJ, Ahn Y, Shin DI. The influence of gastrectomy on the change of bone metabolism and bone density. Korean J Intern Med. 2000. 15:25–31.

18. Thompson GR. Vitamin D deficiency after gastrectomy. Sci Basis Med Annu Rev. 1970. 260–275.

19. Tovey FI, Hall ML, Ell PJ, Hobsley M. A review of postgastrectomy bone disease. J Gastroenterol Hepatol. 1992. 7:639–645.

20. Holick MF. The vitamin D epidemic and its health consequences. J Nutr. 2005. 135:2739S–2748S.

21. Filipponi P, Gregorio F, Cristallini S, Mannarelli C, Blass A, Scarponi AM, et al. Partial gastrectomy and mineral metabolism: effects on gastrin-calcitonin release. Bone Miner. 1990. 11:199–208.

22. Nilas L, Christiansen C. Influence of PTH and 1,25(OH)2D on calcium homeostasis and bone mineral content after gastric surgery. Calcif Tissue Int. 1985. 37:461–466.

23. Maier GW, Kreis ME, Zittel TT, Becker HD. Calcium regulation and bone mass loss after total gastrectomy in pigs. Ann Surg. 1997. 225:181–192.

24. Holick MF. Vitamin D deficiency. N Engl J Med. 2007. 357:266–281.

25. Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R. Skeletal sequelae of cancer and cancer treatment. J Cancer Surviv. 2009. 3:75–88.

26. Davies JH, Evans BA, Jenney ME, Gregory JW. In vitro effects of combination chemotherapy on osteoblasts: implications for osteopenia in childhood malignancy. Bone. 2002. 31:319–326.

27. Xian CJ, Cool JC, Pyragius T, Foster BK. Damage and recovery of the bone growth mechanism in young rats following 5-fluorouracil acute chemotherapy. J Cell Biochem. 2006. 99:1688–1704.

28. Ehrhart N, Eurell JA, Tommasini M, Constable PD, Johnson AL, Feretti A. Effect of cisplatin on bone transport osteogenesis in dogs. Am J Vet Res. 2002. 63:703–711.

29. Gorouhi F, Islami F, Bahrami H, Kamangar F. Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis. Br J Cancer. 2008. 98:1443–1451.

30. Fernandez-Martin JL, Kurian S, Farmer P, Nanes MS. Tumor necrosis factor activates a nuclear inhibitor of vitamin D and retinoid-X receptors. Mol Cell Endocrinol. 1998. 141:65–72.

31. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009. 122:896–903.

32. Chung HY. Osteoporosis diagnosis and treatment 2007. J Korean Endocr Soc. 2008. 23:76–108.

33. World Health Organization. 1994 Report No.: WHO Technical Report Series 843. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva (Switzerland): World Health Organization.

34. Jang JY, Chung HY, Hwang YC, Jeong IK, Ahn KJ, Kwon MK, et al. Dietary calcium intake and bone metabolism in Korean postmenopausal women. Korean J Bone Metab. 2008. 15:143–149.

35. NIH Consensus Conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA. 1994. 272:1942–1948.

36. Iwamoto J, Uzawa M, Sato Y, Takeda T, Matsumoto H. Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients. J Bone Miner Metab. 2010. 28:202–208.

37. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996. 97:2692–2696.

38. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008. 83:1032–1045.

39. Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med. 2006. 119:4 Suppl 1. S3–S11.

40. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996. 348:1535–1541.